Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Human Glucocerebrosidase · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Human Glucocerebrosidase (prGCD) | DRUG | - |
Human Glucocerebrosidase is an investigational small molecule being developed for the treatment of Gaucher Disease, a rare inherited metabolic disorder. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Human Glucocerebrosidase is being developed by Protalix BioTherapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol PLX. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
Human Glucocerebrosidase is in Phase 1 clinical development. A Phase 1 single dose-escalation safety study has been completed, involving 6 participants with Gaucher Disease. The drug remains investigational and has not received regulatory approval.
Human Glucocerebrosidase has been studied in one clinical trial, identified as NCT00258778, titled 'Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)'. This Phase 1 study, which enrolled 6 participants with Gaucher Disease, has been completed.
Human Glucocerebrosidase is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Gaucher Disease. The completed Phase 1 trial was a safety study, and the drug has not yet progressed to later-stage trials or received marketing authorization.